Search results for "GASTROINTESTINAL"

showing 10 items of 1016 documents

Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference.

2016

Abstract Patients with cirrhosis present with hemostatic alterations secondary to reduced availability of pro-coagulant and anti-coagulant factors. The net effect of these changes is a rebalanced hemostatic system. The Italian Association of the Study of the Liver (AISF) and the Italian Society of Internal Medicine (SIMI) promoted a consensus conference on the hemostatic balance in patients with cirrhosis. The consensus process started with the review of the literature by a scientific board of experts and ended with a formal consensus meeting in Rome in December 2014. The statements were graded according to quality of evidence and strength of recommendations, and approved by an independent …

Liver CirrhosisCirrhosisBleeding; Cirrhosis; Hemostasis; Thrombosis; Hepatology; GastroenterologySettore MED/09 - Medicina InternaBleeding; Cirrhosis; Hemostasis; Thrombosis; Anticoagulants; Coagulants; Drug Monitoring; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Postoperative Hemorrhage; Thrombosis; Blood Coagulation Tests; Hemostasis; Hepatology; Gastroenterology0302 clinical medicineEsophageal and Gastric VariceBlood coagulation testConsensus conferenceGastroenterologyThrombosisOptimal managementCirrhosisCoagulant030220 oncology & carcinogenesisThrombosi030211 gastroenterology & hepatologyBlood Coagulation TestsDrug MonitoringGastrointestinal HemorrhageHumanmedicine.medical_specialtyLiver CirrhosiBleeding; Cirrhosis; Hemostasis; Thrombosis; Gastroenterology; HepatologyPostoperative HemorrhageEsophageal and Gastric VaricesNO03 medical and health sciencesInternal medicinemedicineHumansIn patientIntensive care medicineHemostasisCirrhosiHepatologybusiness.industryCoagulantsBleeding; Cirrhosis; Hemostasis; ThrombosisBleedingAnticoagulantAnticoagulantsThrombosisHepatologyHemostasiBlood Coagulation Testmedicine.diseaseSurgeryHemostasisbusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Transjugular intrahepatic portosystemic shunt (TIPS) complications: what diagnostic radiologists should know

2022

Transjugular intrahepatic portosystemic shunt (TIPS) is an effective therapy for portal hypertension complications and can successfully treat variceal bleeding and refractory ascites. Although TIPS is relatively safe, procedural- or shunt-related morbidity can reach 20%, and procedural complications have a fatality rate of 2%. Delayed recognition and treatment of TIPS complications can lead to life-threatening clinical scenarios. Complications can vary from stent migration or malpositioning to nontarget organ injury, TIPS dysfunction, encephalopathy, or liver failure. This review aims to outline the role of diagnostic radiology in assessing post-TIPS complications.[GRAPHICS].

Liver CirrhosisComplicationsRadiological and Ultrasound TechnologyUrologyGastroenterologyEsophageal and Gastric VaricesTransjugular intrahepatic portosystemic shuntImagingTreatment OutcomeHepatic EncephalopathyRadiologistsTIPSHumansRadiology Nuclear Medicine and imagingPortasystemic Shunt Transjugular IntrahepaticGastrointestinal HemorrhageAbdominal Radiology
researchProduct

Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis

2003

Abstract Background & aims: Emergency sclerotherapy is used as a first-line therapy for variceal bleeding in cirrhosis, although pharmacologic treatment stops bleeding in most patients. We performed a meta-analysis comparing emergency sclerotherapy with pharmacologic treatment. Methods: MEDLINE (1968–2002), EMBASE (1986–2002), and the Cochrane Library (2002;4) were searched to retrieve randomized controlled trials comparing sclerotherapy with vasopressin (± nitroglycerin), terlipressin, somatostatin, or octreotide for variceal bleeding in cirrhosis. Outcome measures were failure to control bleeding, rebleeding, blood transfusions, adverse events, and mortality. Results: Fifteen trials were …

Liver CirrhosisEmergency Medical ServicesVariceal bleedingmedicine.medical_specialtyCirrhosisVasopressinsmedicine.medical_treatmentOctreotideLypressinCochrane LibraryEsophageal and Gastric VaricesOctreotideGastroenterologyHemostaticslaw.inventionRandomized controlled triallawVasoactiveInternal medicineSclerotherapySclerotherapyHumansVasoconstrictor AgentsMedicineAdverse effectRandomized Controlled Trials as TopicHepatologybusiness.industryGastroenterologymedicine.diseaseHormonesSurgeryAnesthesiaMeta-analysisAcute DiseaseTerlipressinVaricesGastrointestinal HemorrhageSomatostatinbusinessTerlipressinmedicine.drugEuropean Journal of Gastroenterology & Hepatology
researchProduct

Clinical aspects of bleeding complications in cirrhotic patients

2000

Liver disease is a frequent cause of haemostatic abnormalities, which may lead to overt or occult bleeding. Clinical manifestations of hepatic coagulopathy include upper and lower gastrointestinal haemorrhage, easy bruising and bleeding from gums, nose or the female genital tract. The most significant bleeding problem among patients with chronic liver disease is blood loss due to portal hypertension. About 30% of subjects with oesophageal or gastric varices resulting from cirrhosis have an episode of gastrointestinal bleeding in their lifetime. Risk factors for the first episode of variceal bleeding include the severity of liver dysfunction, large varices, and the presence of endoscopic red…

Liver CirrhosisMaleGastrointestinal bleedingmedicine.medical_specialtyCirrhosisBiopsyDysfunctional uterine bleedingHemorrhageFactor VIIaChronic liver diseasePostoperative ComplicationsmedicineHumansFirst episodebusiness.industryBacterial InfectionsHematologyGeneral MedicineGastric varicesmedicine.diseaseRecombinant ProteinsSurgeryPortal hypertensionFemalemedicine.symptombusinessVaricesBlood Coagulation & Fibrinolysis
researchProduct

The PHES battery does not detect all cirrhotic patients with early neurological deficits, which are different in different patients.

2017

Background and aims The psychometric hepatic encephalopathy score (PHES) is the “gold standard” for minimal hepatic encephalopathy (MHE) diagnosis. Some reports suggest that some cirrhotic patients “without” MHE according to PHES show neurological deficits and other reports that neurological alterations are not homogeneous in all cirrhotic patients. This work aimed to assess whether: 1) a relevant proportion of cirrhotic patients show neurological deficits not detected by PHES; 2) cirrhotic patients with mild neurological deficits are a homogeneous population or may be classified in sub-groups according to specific deficits. Methods Cirrhotic patients “without” (n = 56) or “with” MHE (n = 4…

Liver CirrhosisMalePathologyPediatricsCirrhosisPsychometricsSocial Scienceslcsh:MedicineNeuropsychological Tests0302 clinical medicineMedicine and Health SciencesPsychologyCluster AnalysisAttentionlcsh:ScienceHepatic encephalopathyCognitive Impairmenteducation.field_of_studyMultidisciplinaryCognitive NeurologyLiver DiseasesMiddle AgedNeurologyCirrhosisOncologyFemale030211 gastroenterology & hepatologyResearch Articlemedicine.medical_specialtyPsychometricsCognitive NeurosciencePopulationGastroenterology and HepatologyCarcinomas03 medical and health sciencesNeuropsychologyGastrointestinal TumorsmedicineHumanseducationNeuropsychological TestingAgedWorking memorybusiness.industryGold standardlcsh:RCognitive PsychologyCase-control studyBiology and Life SciencesCancers and NeoplasmsReproducibility of ResultsHepatocellular Carcinomamedicine.diseasePatient Outcome AssessmentCase-Control StudiesHepatic EncephalopathyStroop TestCognitive Sciencelcsh:QbusinessPsychomotor Performance030217 neurology & neurosurgeryNeuroscienceFollow-Up StudiesStroop effectPLoS ONE
researchProduct

Platelet count does not predict bleeding in cirrhotic patients: Results from the PRO-LIVER Study

2018

OBJECTIVES: Thrombocytopenia is a hallmark for patients with cirrhosis and it is perceived as a risk factor for bleeding events. However, the relationship between platelet count and bleeding is still unclear. METHODS: We investigated the relationship between platelet count and major or clinical relevant nonmajor bleedings during a follow-up of ∼4 years. RESULTS: A total of 280 cirrhotic patients with different degrees of liver disease (67% males; age 64±37 years; 47% Child–Pugh B and C) were followed up for a median of 1,129 (interquartile range: 800–1,498) days yielding 953.12 patient-year of observation. The annual rate of any significant bleeding was 5.45%/year (3.57%/year and 1.8…

Liver CirrhosisMaleSettore MED/09 - Medicina Interna030204 cardiovascular system & hematologyGastroenterologySeverity of Illness IndexcjirrhosisACTIVATION0302 clinical medicineRisk FactorsMedicinePlateletProspective StudiesProspective cohort studyRISKAged 80 and overmedicine.diagnostic_testPRO-LIVERPlatelet cirrhosis gastrointestinal bleedingPlateletGastroenterologyASSOCIATIONMiddle AgedPrognosisItaly030211 gastroenterology & hepatologyFemaleGastrointestinal HemorrhageHumanAdultPlateletsmedicine.medical_specialtyPrognosiLiver CirrhosiMEDLINECOAGULATIONgastrointestinal bleedingSocio-culturaleHemorrhageHepatology; GastroenterologyFollow-Up Studie03 medical and health sciencesText miningInternal medicineSeverity of illnessENDOTOXEMIAPro-Liver StudyHumansHEMOSTASISInternational Normalized RatioAgedProportional Hazards ModelsProthrombin timeCirrhosiHepatologyPlatelet Count Bleeding Liver Cirrhosisbusiness.industryProportional hazards modelPlatelet CountRisk FactorcirrhosisHepatologybleedingThrombocytopeniaProspective StudieTHROMBOSISPlatelets cjirrhosis bleeding PRO-LIVERProportional Hazards ModelProthrombin TimebusinessDECOMPENSATED CIRRHOSISFollow-Up Studies
researchProduct

Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience

2019

INTRODUCTION: The Baveno VI consensus guidelines and an expanded algorithm suggest that transient elastography (TE) and platelet (PLT) count can be used to identify patients with cirrhosis who can avoid esophagogastroduodenoscopy (EGD). The primary aims of this study were to assess the ability of a simple algorithm, which uses only laboratory parameters, to predict medium/large esophageal varices (EV) in patients with hepatitis C virus (HCV) and cirrhosis from the Rete Sicilia Selezione Terapia-HCV (RESIST-HCV) cohort and to compare the performance of the algorithm with Baveno VI and Expanded Baveno VI criteria. The secondary aim was to assess the role of TE in ruling out large EV. METHODS:…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisBAVENO VI CRITERIA PORTAL-HYPERTENSION CONSENSUS WORKSHOP LIVER STIFFNESS PLATELET COUNT CIRRHOSIS DIAGNOSIS;Esophageal and Gastric Varices03 medical and health sciences0302 clinical medicineRESIST-HCVmedicineesophageal varicesHumansBaveno VIEndoscopy Digestive SystemSerum AlbuminAgedHepatologymedicine.diagnostic_testPlatelet CountEsophagogastroduodenoscopybusiness.industryfungiGastroenterologyReproducibility of Resultsfood and beveragesHepatitis C ChronicMiddle Agedmedicine.diseasetransient elastographyEndoscopyLogistic ModelsCIRRHOSIS PORTAL HYPERTENSION VARICES STIFFNESS030220 oncology & carcinogenesistransient elastography esophageal varices HCV RESIST-HCV Baveno VIMultivariate AnalysisHCVElasticity Imaging TechniquesFemale030211 gastroenterology & hepatologyRadiologyGastrointestinal HemorrhagebusinessVaricesTransient elastographyAlgorithms
researchProduct

The Role of Liver in Determining Serum Colon-Derived Uremic Solutes.

2015

Evidence has shown that indoxyl sulfate (IS) and p-cresyl sulfate (PCS) may be alternative predictors of clinical outcomes in chronic kidney disease (CKD). Both toxins are derived from the gastrointestinal tract and metabolised in the liver. However, it is unclear whether the liver affects the production of IS and PCS. Here, we explore the association between IS and PCS levels in liver cirrhosis and a CKD-based cohort (N = 115). Liver and kidney function was assessed and classified by a Child-Pugh score (child A–C) and a modified version of the Modification of Diet in Renal Disease (MDRD) equation (Stages 1–4), respectively. An animal model was also used to confirm the two toxin levels in a…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisColonlcsh:MedicineUrineSulfuric Acid EstersKidneyGastroenterologyCohort StudiesRats Sprague-DawleyCresolsInternal medicinemedicineAnimalsHumansRenal Insufficiency Chroniclcsh:ScienceAgedUremiaKidneyGastrointestinal tractMultidisciplinarymedicine.diagnostic_testbusiness.industrylcsh:RKidney metabolismMiddle Agedmedicine.diseaseUremiahumanitiesRatsGastrointestinal TractDisease Models Animalmedicine.anatomical_structureEndocrinologyTreatment OutcomeLiverMultivariate AnalysisLinear Modelslcsh:QFemaleLiver function testsbusinessIndicanKidney diseaseResearch ArticlePloS one
researchProduct

TIPS for Prevention of Recurrent Bleeding in Patients with Cirrhosis: Meta-analysis of Randomized Clinical Trials

1999

To compare the effects of transjugular intrahepatic portosystemic shunt (TIPS) creation with those of endoscopic treatment with or without propranolol administration (i.e, conventional treatment) on recurrent bleeding, encephalopathy, and mortality by using meta-analysis of 11 published randomized clinical trials.Data from 11 relevant studies were retrieved by means of computerized and manual search. The combinability of the studies was assessed in terms of clinical and statistical criteria. Data were extracted on the basis of the intention-to-treat principle, and treatment effects were measured as risk differences between TIPS creation and conventional treatment. Pooled estimates were comp…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosismedicine.medical_treatmentEncephalopathyEsophageal and Gastric Variceslaw.inventionRandomized controlled trialRecurrenceRisk FactorslawSclerotherapymedicineSclerotherapyHumansRadiology Nuclear Medicine and imagingbusiness.industryLiver DiseasesHemostasis EndoscopicMiddle Agedmedicine.diseaseSurgeryHepatic EncephalopathyMeta-analysisPortal hypertensionFemalePortasystemic Shunt Transjugular IntrahepaticGastrointestinal HemorrhageVaricesbusinessTransjugular intrahepatic portosystemic shuntRadiology
researchProduct

Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial.

1998

beta-Blockers and sclerotherapy prevent long-term upper digestive rebleeding in cirrhosis but they seem ineffective for early rebleeding. We compared octreotide with a placebo for the prevention of early rebleeding in cirrhotic patients. After control of acute upper digestive bleeding, 262 consecutive cirrhotic patients were randomized to octreotide 100 microgram subcutaneously three times a day for 15 days (n = 131) or to the placebo (n = 131), in a double blind pragmatic trial in which beta-blockers and/or sclerotherapy were allowed together with the experimental treatment. Separate randomization and analysis were performed according to whether patients were eligible for beta-blockers and…

Liver CirrhosisMalemedicine.medical_specialtyRandomizationmedicine.medical_treatmentAdrenergic beta-AntagonistsOctreotidePlaceboOctreotideHemostaticsPlacebosDouble-Blind MethodMelenaRecurrenceSclerotherapymedicineSclerotherapyHumansHepatologybusiness.industryHematemesisLength of StayMiddle AgedSurgeryClinical trialSurvival RateTreatment OutcomeChemoprophylaxisFemaleComplicationVaricesbusinessGastrointestinal Hemorrhagemedicine.drugHepatology (Baltimore, Md.)
researchProduct